Creo Medical Group (LON:CREO) Stock Price Down 1.8% – Should You Sell?

Creo Medical Group PLC (LON:CREO) shares traded down 1.8% during trading on Friday. The stock traded as low as GBX 11.05 and last traded at GBX 11.05. 175,788 shares changed hands during trading, a decline of 78% from the average daily volume of 787,611 shares. The stock had previously closed at GBX 11.25.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a research note on Thursday, July 23rd.

Creo Medical Group Stock Performance

The firm has a 50 day moving average of GBX 11.86 and a two-hundred day moving average of GBX 12.66. The company has a debt-to-equity ratio of 8.09, a current ratio of 2.79 and a quick ratio of 2.19. The stock has a market cap of £49.63 million, a PE ratio of -2.21 and a beta of 1.56.

Creo Medical Group (LON:CREO) last posted its earnings results on Wednesday, September 30th. The company reported GBX (2) EPS for the quarter. Creo Medical Group had a negative net margin of 268.57% and a negative return on equity of 38.29%. Research analysts predict that Creo Medical Group PLC will post -10.08 EPS for the current fiscal year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.